Development of a novel oral drug delivery platform based on Hydrogel-Doped Nanoparticles – HyDNano
HyDNano aims at developing an original hybrid system made of nanomedicine loaded into an hydrogel matrix to control local or systemic drug delivery following oral administration. This strategy represents an innovative and unique approach for achieving a controlled release of actives, via oral route, to enhance the residence time and contact of drugs with the intestine and to promote, using tailored nanomedicines, their interaction with epithelia membrane or the permeability. Key parameters as physical, mechanical and biological mechanisms governing the diffusion rate of nanosystems, release and permeation of drugs, through both hydrogel matrix and mucus layer, will be described. The in vivo proof-of-concept will be done in healthy and in Inflammatory Bowel Disease (chronic intestinal pathology) mouse model. The multifunctional approach here presented would lead to a more effective solution for mucosal oral delivery that could potentially reach clinical stages in shorter times.
Project coordination
Giovanna Lollo (LABORATOIRE D'AUTOMATIQUE ET DE GENIE DES PROCEDES)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
Partner
LAGEP LABORATOIRE D'AUTOMATIQUE ET DE GENIE DES PROCEDES
Help of the ANR 248,400 euros
Beginning and duration of the scientific project:
August 2019
- 36 Months